Neurocrine BiosciencesFRA:NB3 +0.23%94 Days Payable is 739.15 as of Mar. 2026, which is 41% below its 10-year median of 1,251.74. GuruFocus rates FRA:NB3 with a GF Score™ of 94/100 and a GF Value™ of €163.30 (Fairly Valued). The stock has 6 warning signs investors should review. Among 922 Drug Manufacturers companies, Neurocrine Biosciences ranks better than 95.99% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NB3 vs VTRS, ELAN, UTHR: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurocrine Biosciences Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Neurocrine Biosciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences (FRA:NB3) has a Days Payable of 739.15 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Neurocrine Biosciences and its competitors. This is 41% below median its historical median of 1,251.74. Over the past decade, Neurocrine Biosciences' Days Payable has ranged from 717.39 to 1,967.57. According to the industry distribution chart, Neurocrine Biosciences ranks #37 out of 922 companies in the Drug Manufacturers industry, placing it in the top 4%.
Is Neurocrine Biosciences' Days Payable too high?
Neurocrine Biosciences' current Days Payable of 739.15 is 41% below median its 10-year median of 1,251.74. Over the past 10 years, this metric has ranged from a low of 717.39 to a high of 1,967.57. The Drug Manufacturers industry median Days Payable is 90.61. Neurocrine Biosciences' value of 739.15 is 715.7% above this industry median. Based on the distribution chart, Neurocrine Biosciences ranks #37 out of 922 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Neurocrine Biosciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Days Payable compare to VTRS and ELAN?
According to the Drug Manufacturers industry distribution chart, Neurocrine Biosciences ranks #37 out of 922 companies for Days Payable. This places Neurocrine Biosciences in the top 4% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.61. Neurocrine Biosciences' value of 739.15 is 715.7% above this benchmark. Historically, Neurocrine Biosciences' own Days Payable has ranged from 717.39 to 1,967.57 over the past decade. While the company's 10-year median is 1,251.74 vs. the industry median of 90.61, Neurocrine Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.61, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurocrine Biosciences's current Days Payable of 739.15 is 715.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Neurocrine Biosciences and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurocrine Biosciences's current Days Payable is 739.15, which is 41% below median its own 10-year median of 1,251.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (FRA:NB3) is currently considered Fairly Valued. The stock's GF Value™ is €163.30, compared to a current price of €153.55 — trading 6% below its estimated fair value. The current Days Payable is 739.15, which is 41% below median its 10-year median of 1,251.74 and 715.7% above the Drug Manufacturers industry median of 90.61. Neurocrine Biosciences' overall GF Score™ is 94/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Neurocrine Biosciences (FRA:NB3), the current Days Payable is 739.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neurocrine Biosciences (FRA:NB3) Overvalued in 2026?
Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued.
The current stock price of €153.55 is trading 6% below its estimated GF Value™ of €163.30.
GuruFocus considers Neurocrine Biosciences to be Fairly Valued.
Key valuation signals for FRA:NB3:
Days Payable: 739.15 (41% below median its 10-year median of 1,251.74)
GF Value™: €163.30 vs. price of €153.55 (6% below fair value)
Industry Position: 715.7% above the Drug Manufacturers median (#37 of 922)
No single metric tells the full story. See the FRA:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
94GF Score
Get the complete analysis for FRA:NB3
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NB3 has been successfully added to your 
